

# MindBio Therapeutics - AI voice analytics for real-time drug and alcohol intoxication detection

Transforming workplace safety and compliance potential with AI-powered voice-based intoxication screening

## MindBio Advances Large-Scale Deployment of Voice Intoxication Detection Through Integrated Edge AI Hardware-Software Platform

Feb 18, 2026, 08:06 GMT-5 · Refinitiv · 3 min read



MBIO -6.38%


(TheNewswire)

Vancouver, British Columbia -TheNewswire - February 18, 2026 - MindBio Therapeutics Corp.  (Frankfurt: WF6) (OTCQB: MBQIF) (“MindBio” or the “Company”), a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection, today announced it has

Strategy, business, and products

The newswire.ca

MBIO chart >



Analyze on Supercharts

**Saint Petersburg, Florida Mar 5, 2026 ([IssueWire.com](https://www.issuewire.com))** - Disseminated on behalf of MindBio Therapeutics

### What This Company Does

MindBio built an AI model trained on 50+ million voice data points from clinical drug and alcohol trials. The technology analyzes short voice samples to predict intoxication levels in real time, no hardware, no blood draw, no breathalyzer. The consumer app (Booze AI) launched in 2025 as the first voice-activated blood alcohol estimator on smartphones. The company is now developing enterprise versions for workplaces, mining, law enforcement, and healthcare.

### Why It Matters

Traditional impairment testing is invasive, expensive, and episodic. Voice-based detection is software-only, scalable, and can be deployed remotely. If the accuracy holds in commercial environments, this addresses massive markets: workplace safety compliance, road safety, addiction treatment monitoring, and insurance risk. The company announced on February 18, 2026 that it is building a dedicated Edge AI hardware device for the mining sector, with Chile as its first target market and prototype completion expected Q2 2026. Each device would carry recurring software revenue.

## Leadership Highlights

Chairman Gavin Upiter founded Generic Health (sold to Lupin Pharmaceuticals), served as Australian CEO of Amneal Pharmaceuticals (NYSE: AMRX), and held executive roles at Bristol-Myers Squibb and Slade Health. CEO Justin Hanka is an investment banker and co-founder who remains a significant shareholder.

## Recent Milestones

### Date

### Event

#### Jan 2025

Discovered speech-based intoxication detection from clinical trial data; LOI to acquire Life AI Corp

#### Mar 2025

Closed acquisition of Life AI Corp and Booze AI application

#### May 2025

Completed Booze AI software development; prepared for consumer launch

#### Nov 2025

400:1 share consolidation approved and completed via CSE

#### Jan 2026

Listed on OTCQB; launched US showcase of voice AI detection tech

#### Feb 2026

Announced Edge AI hardware platform for mining; initiated Chile operations

For more information visit: <https://mindbiotherapeutics.com>

[https://www.tradingview.com/news/reuters.com%2C2026-02-18%3Anewsml\\_Tnw971MHZ%3A0-mind-bio-advances-large-scale-deployment-of-voice-intoxication-detection-through-integrated-edge-ai-hardware-software-platform/](https://www.tradingview.com/news/reuters.com%2C2026-02-18%3Anewsml_Tnw971MHZ%3A0-mind-bio-advances-large-scale-deployment-of-voice-intoxication-detection-through-integrated-edge-ai-hardware-software-platform/)

Sponsored Article  
by Street Scope Media, LLC  
[Communicated Disclaimer](#)

#### Recent Milestones

Date	Event
Jan 2025	Discovered speech-based intoxication detection from clinical trial data; LHM to acquire Life AI Corp
Mar 2025	Closed acquisition of Life AI Corp and Booz AI application
May 2025	Completed Booz AI software development; prepared for consumer launch
Nov 2025	4000 share consolidation approved and completed via CSE
Jan 2026	Listed as OTCQB; launched US showcase of voice AI detection tech
Feb 2026	Announced Edge AI hardware platform for mining; initiated Chile operations

## Media Contact

Street Scope Media LLC

\*\*\*\*\*@streetscopemedia.com

3214416545

30 N Gould st

Source : Mindbio Therapeutics

[See on IssueWire](#)